$COCP this thing is attractive for many reasons. 1) most penny bios are high risk for dilution or r/s. Not so much here. No debt to speak of at this point and enough cash to get through the year so more than likely should not see an offering. float is healthy and staying above $1 so no need for r/s. Two big checkoffs right there as far as risk. Reason 2) multiple different products in pipe so if any singular one does not pan out it isn’t a do or die thing.. maybe a %10-20 drop worst case. BUT if any hint of positive news, especially on the covid therapeutic or influenza the gains could be enormous %100’s were talking. So from a risk reward perspective this is a no brainer. Id be very scarred to short something like this.